Examine the comparative availability of DPP-4 Inhibitor versus Alfa-glycosidase inhibitor for the type 2 diabetic patient who was treated with Pioglitazone or Metohormine
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-UMIN000004675
- Lead Sponsor
- Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 114
Not provided
1)Patients with type 1 diabetes 2)History of severe ketosis, diabetic coma or precoma within 6 months 3)Patients with severe infections, before or after operation, or with serious trauma 4)Patients with exceeding the moderate renal impairment 5)Patients with history of stroke, MI or other sever vascular complication which required a hospitalization within six months. 6)Patients receiving DPP-4 Inhibitor except Sitagliptin 7)Patients receiving Alfa-glycosidase inhibitor, Sulfonylurea or Glinide during obtaining the informed consent or received Insulin treatment in the past 2 months. 8)Patients who are pregnant, breastfeeding or intention to becoming pregnant 9)Having allergy to DPP-4 Inhibitor or Alfa-glycosidase inhibitor 10)Other patients determined to be inappropriate by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of HbA1c from the baseline to 12 weeks later
- Secondary Outcome Measures
Name Time Method